Search

Your search keyword '"Eder, Lihi"' showing total 820 results
Start Over Author "Eder, Lihi"
820 results on '"Eder, Lihi"'

6. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Author

Coates, Laura C., Soriano, Enrique R., Corp, Nadia, Bertheussen, Heidi, Callis Duffin, Kristina, Campanholo, Cristiano B., Chau, Jeffrey, Eder, Lihi, Fernández-Ávila, Daniel G., FitzGerald, Oliver, Garg, Amit, Gladman, Dafna D., Goel, Niti, Helliwell, Philip S., Husni, M. Elaine, Jadon, Deepak R., Katz, Arnon, Laheru, Dhruvkumar, Latella, John, Leung, Ying-Ying, Lindsay, Christine, Lubrano, Ennio, Mazzuoccolo, Luis Daniel, Mease, Philip J., O’Sullivan, Denis, Ogdie, Alexis, Olsder, Wendy, Palominos, Penelope Esther, Schick, Lori, Steinkoenig, Ingrid, de Wit, Maarten, van der Windt, D. A., and Kavanaugh, Arthur

Published
2022
Full Text
View/download PDF

11. Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada Living Treatment Recommendations for the Management of Axial Spondyloarthritis.

Author

Rohekar, Sherry, Pardo, Jordi Pardo, Mirza, Reza, Aydin, Sibel Z., Bessette, Louis, Richard, Nicolas, Mosher, Dianne, Boyd, Tristan, Chan, Jon, Eder, Lihi, Passalent, Laura, Karam, Elie, Nair, Bindu, Hazlewood, Glen S., Tse, Shirley, Rumsey, Dax, Zummer, Michel, Haroon, Nigil, Inman, Robert, and Gladman, Dafna D.

Published
2025
Full Text
View/download PDF

12. Cardio-Rheumatology Insights Into Hypertension: Intersection of Inflammation, Arteries, and Heart.

Author

Akhtari, Shadi, Harvey, Paula J, and Eder, Lihi

Subjects
JOINT pain, RHEUMATISM, HYPERTENSION risk factors, SYSTEMIC lupus erythematosus, RHEUMATOID arthritis
Abstract

There is an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) in patients with inflammatory rheumatic diseases (IRD) including rheumatoid arthritis, systemic lupus erythematosus, psoriatic arthritis, and systemic sclerosis. The mechanism for the development of ASCVD in these conditions has been linked not only to a higher prevalence and undertreatment of traditional cardiovascular (CV) risk factors but importantly to chronic inflammation and a dysregulated immune system which contribute to impaired endothelial and microvascular function, factors that may contribute to accelerated atherosclerosis. Accurate ASCVD risk stratification and optimal risk management remain challenging in this population with many barriers that include lack of validated risk calculators, the remitting and relapsing nature of underlying disease, deleterious effect of medications used to manage rheumatic diseases, multimorbidity, decreased mobility due to joint pain, and lack of clarity about who bears the responsibility of performing CV risk assessment and management (rheumatologist vs. primary care provider vs. cardiologist). Despite recent advances in this field, there remain significant gaps in knowledge regarding the best diagnostic and management approach. The evolving field of Cardio-Rheumatology focuses on optimization of cardiovascular care and research in this patient population through collaboration and coordination of care between rheumatologists, cardiologists, radiologists, and primary care providers. This review aims to provide an overview of current state of knowledge about ASCVD risk stratification in patients with IRD, contributing factors including effect of medications, and review of the current recommendations for cardiovascular risk management in patients with inflammatory disease with a focus on hypertension as a key risk factor. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

23. Prevalence and Predictors of Inflammatory Arthritis in Hidradenitis Suppurativa.

Author

Sy, Sheena Maureen T., Eder, Lihi, Jerome, Dana, Obetta, Chikaodili, McKee, Hayley, Mirza, Reza, Pek, Elisabeth, Piguet, Vincent, and Alhusayen, Raed

Subjects
*HIDRADENITIS suppurativa, *AGE of onset, *BLACK people, *INFORMED consent (Medical law), *MULTIVARIATE analysis
Abstract

Hidradenitis Suppurativa (HS) is a chronic, debilitating, auto‐inflammatory condition often associated with inflammatory arthritis, significantly impacting patients' quality of life. Early diagnosis of both conditions is crucial for optimal management. The objective of this study was to determine the prevalence and factors associated with the development of inflammatory arthritis among HS patients. A cross‐sectional study was conducted between November 2021 and February 2023 at an academic dermatology centre in Canada. Adult patients with HS were consecutively sampled, and 52 patients consented to participate and completed assessments. Variables examined included age, sex, HS severity, treatment, ethnicity, family history, lifestyle factors and comorbidities. The main outcomes were rheumatologist‐confirmed inflammatory arthritis diagnosis and associated risk factors. Among 52 patients (24 males, 28 females; mean age: 37.4 years), 12 had inflammatory arthritis. Multivariate analysis revealed that Blacks (OR = 0.10, p < 0.001, CI: 0.026–0.343) and Asians (OR = 0.02, p < 0.001, CI: 0.005–0.109) had lower inflammatory arthritis odds compared to Whites. Every 1‐year increase in age at HS onset correlated with a 1.17‐fold increase in the odds of developing inflammatory arthritis (OR: 1.17, p < 0.001, CI: 1.12–1.24). Smoking (OR = 0.01, p < 0.001, CI: 0.002–0.49), hypertension (OR: 0.23, p = 0.04, CI: 0.057–0.930) and depression (OR: 0.12, p < 0.001, CI: 0.041–0.330) reduced inflammatory arthritis odds. White ethnicity and older age at HS onset were positively associated with inflammatory arthritis, while smoking, hypertension and depression were negatively associated. These findings suggest a distinct subset of HS patients with inflammatory arthritis that warrant further prospective studies. This study contributes to the understanding of inflammatory arthritis in HS patients and emphasises the importance of rheumatology referral during dermatologic clinic visits. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

27. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Author

Gossec, Laure, primary, Kerschbaumer, Andreas, additional, Ferreira, Ricardo J O, additional, Aletaha, Daniel, additional, Baraliakos, Xenofon, additional, Bertheussen, Heidi, additional, Boehncke, Wolf-Henning, additional, Esbensen, Bente Appel, additional, McInnes, Iain B, additional, McGonagle, Dennis, additional, Winthrop, Kevin L, additional, Balanescu, Andra, additional, Balint, Peter V, additional, Burmester, Gerd R, additional, Cañete, Juan D, additional, Claudepierre, Pascal, additional, Eder, Lihi, additional, Hetland, Merete Lund, additional, Iagnocco, Annamaria, additional, Kristensen, Lars Erik, additional, Lories, Rik, additional, Queiro, Rubén, additional, Mauro, Daniele, additional, Marzo-Ortega, Helena, additional, Mease, Philip J, additional, Nash, Peter, additional, Wagenaar, Wendy, additional, Savage, Laura, additional, Schett, Georg, additional, Shoop-Worrall, Stephanie J W, additional, Tanaka, Yoshiya, additional, Van den Bosch, Filip E, additional, van der Helm-van Mil, Annette, additional, Zabotti, Alen, additional, van der Heijde, Désirée, additional, and Smolen, Josef S, additional

Published
2024
Full Text
View/download PDF

32. Author Correction: Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021

Author

Coates, Laura C., Soriano, Enrique R., Corp, Nadia, Bertheussen, Heidi, Callis Duffin, Kristina, Campanholo, Cristiano B., Chau, Jeffrey, Eder, Lihi, Fernández-Ávila, Daniel G., FitzGerald, Oliver, Garg, Amit, Gladman, Dafna D., Goel, Niti, Helliwell, Philip S., Husni, M. Elaine, Jadon, Deepak R., Katz, Arnon, Laheru, Dhruvkumar, Latella, John, Leung, Ying-Ying, Lindsay, Christine, Lubrano, Ennio, Mazzuoccolo, Luis Daniel, Mease, Philip J., O’Sullivan, Denis, Ogdie, Alexis, Olsder, Wendy, Palominos, Penelope Esther, Schick, Lori, Steinkoenig, Ingrid, de Wit, Maarten, van der Windt, D. A., and Kavanaugh, Arthur

Published
2022
Full Text
View/download PDF

33. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update

Author

Gossec, L., Kerschbaumer, A., Ferreira, R.J.O., Aletaha, D., Baraliakos, X., Bertheussen, H., Boehncke, W., Esbensen, B.A., McInnes, I.B., McGonagle, D., Winthrop, K.L., Balanescu, A., Balint, P.V., Burmester, G.R., Cañete, J.D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, P.J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J W, Tanaka, Yoshiya, Van den Bosch, Filip E, van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, Smolen, Josef S, Gossec, L., Kerschbaumer, A., Ferreira, R.J.O., Aletaha, D., Baraliakos, X., Bertheussen, H., Boehncke, W., Esbensen, B.A., McInnes, I.B., McGonagle, D., Winthrop, K.L., Balanescu, A., Balint, P.V., Burmester, G.R., Cañete, J.D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, P.J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J W, Tanaka, Yoshiya, Van den Bosch, Filip E, van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, and Smolen, Josef S

Abstract

Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA.Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined.Results The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed.Conclusion These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.

Published
2024

34. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2023 update

Author

Gossec, Laure, Kerschbaumer, Andreas, Ferreira, Ricardo J. O., Aletaha, Daniel, Baraliakos, Xenofon, Bertheussen, Heidi, Boehncke, Wolf-Henning, Esbensen, Bente Appel, McInnes, Iain B., McGonagle, Dennis, Winthrop, Kevin L, Balanescu, Andra, Balint, Peter V, Burmester, Gerd R., Cañete, Juan D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, Philip J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J.W., Tanaka, Yoshiya, Van Den Bosch, Filip E., van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, Smolen, Josef S, Gossec, Laure, Kerschbaumer, Andreas, Ferreira, Ricardo J. O., Aletaha, Daniel, Baraliakos, Xenofon, Bertheussen, Heidi, Boehncke, Wolf-Henning, Esbensen, Bente Appel, McInnes, Iain B., McGonagle, Dennis, Winthrop, Kevin L, Balanescu, Andra, Balint, Peter V, Burmester, Gerd R., Cañete, Juan D., Claudepierre, Pascal, Eder, Lihi, Hetland, Merete Lund, Iagnocco, Annamaria, Kristensen, Lars Erik, Lories, Rik, Queiro, Rubén, Mauro, Daniele, Marzo-Ortega, Helena, Mease, Philip J., Nash, Peter, Wagenaar, Wendy, Savage, Laura, Schett, Georg, Shoop-Worrall, Stephanie J.W., Tanaka, Yoshiya, Van Den Bosch, Filip E., van der Helm-van Mil, Annette, Zabotti, Alen, van der Heijde, Désirée, and Smolen, Josef S

Abstract

Objective New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA., Objective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA. Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined. Results: The updated recommendations comprise 7 overarching principles and 11 recommendations, and provide a treatment strategy for pharmacological therapies. Non-steroidal anti-inflammatory drugs should be used in monotherapy only for mild PsA and in the short term; oral glucocorticoids are not recommended. In patients with peripheral arthritis, rapid initiation of conventional synthetic disease-modifying antirheumatic drugs is recommended and methotrexate preferred. If the treatment target is not achieved with this strategy, a biological disease-modifying antirheumatic drug (bDMARD) should be initiated, without preference among modes of action. Relevant skin psoriasis should orient towards bDMARDs targeting interleukin (IL)-23p40, IL-23p19, IL-17A and IL-17A/F inhibitors. In case of predominant axial or entheseal disease, an algorithm is also proposed. Use of Janus kinase inhibitors is proposed primarily after bDMARD failure, taking relevant risk factors into account, or in case bDMARDs are not an appropriate choice. Inflammatory bowel disease and uveitis, if present, should influence drug choices, with monoclonal tumour necrosis factor inhibitors proposed. Drug switches and tapering in sustained remission are also addressed. Conclusion: These updated recommendations integrate all currently available drugs in a practical and progressive approach, which will be helpful in the pharmacological management of PsA.

Published
2024

37. Residual Disease Activity In Canadian Patients With Psoriatic Arthritis (PsA) Treated With Advanced Therapies: Results From A Multi-Registry Analysis (UNISON-PsA)

Author

Gladman, Dafna D., primary, Chandran, Vinod, additional, Rosen, Cheryl F., additional, Rohekar, Sherry, additional, Boyd, Tristan, additional, Eder, Lihi, additional, Rahman, Proton, additional, Dutz, Jan, additional, Chan, Jonathan, additional, Haydey, Richard P., additional, Barac, Snezana, additional, Laliberté, Marie-Claude, additional, Girard, Tanya, additional, Fournier, Pierre-André, additional, Sutton, Mitchell, additional, Pereira, Daniel, additional, Chim, Tina, additional, Coupal, Louis, additional, and Choquette, Denis, additional

Published
2024
Full Text
View/download PDF

47. Association between obesity and likelihood of remission or low disease activity status in psoriatic arthritis applying index-based and patient-based definitions of remission: a cross-sectional study

Author

Leung, Ying Ying, primary, Eder, Lihi, additional, Orbai, Ana-Maria, additional, Coates, Laura C, additional, de Wit, Maarten, additional, Smolen, Josef S, additional, Kiltz, Uta, additional, Palominos, Penélope, additional, Canete, Juan D, additional, Scrivo, Rossana, additional, Balanescu, Andra, additional, Dernis, Emanuelle, additional, Meisalu, Sandra, additional, Soubrier, Martin, additional, Kalyoncu, Umut, additional, and Gossec, Laure, additional

Published
2023
Full Text
View/download PDF

48. Residual Disease Activity in Canadian Patients With Psoriatic Arthritis Treated With Advanced Therapies: Results From a Multiregistry Analysis (UNISON-PsA).

Author

Gladman, Dafna D., Chandran, Vinod, Rosen, Cheryl F., Rohekar, Sherry, Boyd, Tristan, Eder, Lihi, Rahman, Proton, Dutz, Jan, Chan, Jonathan, Haydey, Richard P., Barac, Snezana, Laliberté, Marie-Claude, Girard, Tanya, Fournier, Pierre-André, Sutton, Mitchell, Pereira, Daniel, Chim, Tina, Coupal, Louis, and Choquette, Denis

Published
2024
Full Text
View/download PDF

50. Screening and Referral Strategies for the Early Recognition of Psoriatic Arthritis Among Patients With Psoriasis: Results of a GRAPPA Survey

Author

Song, Kaiyang, primary, Webb, Louisa, additional, Eder, Lihi, additional, FitzGerald, Oliver, additional, Goel, Niti, additional, Helliwell, Philip S., additional, Katz, Arnon, additional, Merola, Joseph F., additional, Rosen, Cheryl F., additional, Coates, Laura C., additional, and Poddubnyy, Denis, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results